Regen BioPharma, Inc. Completes Preclinical Experimentation for Its siRNA NR2F6 Checkpoint InhibitorCompany is Currently Preparing IND for New Cancer Immuno-Therapy Drug

Leave a Reply

Your email address will not be published.